OxLDL as a prognostic biomarker of plaque instability in patients qualified for carotid endarterectomy.
Journal
Journal of cellular and molecular medicine
ISSN: 1582-4934
Titre abrégé: J Cell Mol Med
Pays: England
ID NLM: 101083777
Informations de publication
Date de publication:
Jul 2024
Jul 2024
Historique:
revised:
18
04
2024
received:
03
11
2023
accepted:
16
05
2024
medline:
23
7
2024
pubmed:
23
7
2024
entrez:
23
7
2024
Statut:
ppublish
Résumé
Atherosclerotic plaque instability increases the risk of stroke. As such, determining the nature of an instability atherosclerotic plaque may speed up qualification for carotid endarterectomy (CEA), thus reducing the risk of acute vascular events. The aim of the study was to determine the diagnostic value of oxidized LDL cholesterol (ox-LDL), matrix metalloproteinase 9 (MMP-9) and 8-hydroxy-2'-deoxyguanosine (8-OHdG) in serum as a prognostic markers of instability atherosclerotic plaques. Serum was collected from 67 patients who underwent CEA in accordance with the qualification criteria. The levels of ox-LDL, MMP-9 and 8-OHdG were assessed by ELISA. The predictive value of the markers was determined based on an ROC curve, and the cut-off points with the highest sensitivity and specificity were determined. Patients with unstable atherosclerotic plaque had significantly higher serum ox-LDL, MMP-9 and 8-OHdG values. It was found that in patients before CEA, ox-LDL >31.4 ng/mL was associated with an 82.5% probability of unstable atherosclerotic plaque, MMP-9 >113.1 ng/mL with 78.6%, and 8-OHdG >2.15 ng/mL with 64.7%. Multivariate regression analysis found ox-LDL to be an independent factor associated with plaque instability. Patients with unstable plaques tend to have higher serum levels of ox-LDL, MMP-9 and 8-OHdG compared to those with stable plaques. The optimal cut-off point for ox-LDL (AUC 0.86, p <0.0001) was 31.14 ng/mL, with 91.18% sensitivity and 78.79% specificity. The high sensitivity and specificity of ox-LDL suggests that it can be used as an independent marker of plaque instability.
Substances chimiques
Lipoproteins, LDL
0
oxidized low density lipoprotein
0
Biomarkers
0
Matrix Metalloproteinase 9
EC 3.4.24.35
8-Hydroxy-2'-Deoxyguanosine
88847-89-6
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e18459Informations de copyright
© 2024 The Author(s). Journal of Cellular and Molecular Medicine published by Foundation for Cellular and Molecular Medicine and John Wiley & Sons Ltd.
Références
Stone GW, Maehara A, Lansky AJ, et al. A prospective natural‐history study of coronary atherosclerosis. N Engl J Med. 2011;364:226‐235. doi:10.1056/nejmoa1002358
Liang M. The vulnerable plaque: the real villain in acute coronary syndromes, open cardiovasc. Med J. 2011;5:123‐129. doi:10.2174/1874192401105010123
Sigala F, Kotsinas A, Savari P, et al. Oxidized LDL in human carotid plaques is related to symptomatic carotid disease and lesion instability. J Vasc Surg. 2010;52:704‐713. doi:10.1016/j.jvs.2010.03.047
Munjal A, Khandia R. Atherosclerosis: orchestrating cells and biomolecules involved in its activation and inhibition. Elsevier Ltd. 2020;120:85‐122. doi:10.1016/bs.apcsb.2019.11.002
Dwivedi A, Änggård EE, Carrier MJ. Oxidized LDL‐mediated monocyte adhesion to endothelial cells does not involve NFκB. Biochem Biophys Res Commun. 2001;284:239‐244. doi:10.1006/bbrc.2001.4955
Abilleira S, Bevan S, Markus HS. The role of genetic variants of matrix metalloproteinases in coronary and carotid atherosclerosis. J Med Genet. 2006;43:897‐901. doi:10.1136/jmg.2006.040808
Di Minno A, Turnu L, Porro B, et al. 8‐Hydroxy‐2‐Deoxyguanosine levels and cardiovascular disease: a systematic review and meta‐analysis of the literature, antioxidants redox. Signals. 2016;24:548‐555. doi:10.1089/ars.2015.6508
Chen KH, Srivastava DK, Singhal RK, Jacob S, Ahmed AE, Wilson SH. Modulation of base excision repair by low density lipoprotein, oxidized low density lipoprotein and antioxidants in mouse monocytes. Carcinogenesis. 2000;21:1017‐1022. doi:10.1093/carcin/21.5.1017
Boiteux S, Radicella JP. The human OGG1 gene: structure, functions, and its implication in the process of carcinogenesis. Arch Biochem Biophys. 2000;377:1‐8. doi:10.1006/abbi.2000.1773
Gackowski D, Kruszewski M, Jawien A, Ciecierski M, Olinski R. Further evidence that oxidative stress may be a risk factor responsible for the development of atherosclerosis. Free Radic Biol Med. 2001;31:542‐547. doi:10.1016/S0891-5849(01)00614-1
Naylor R, Rantner B, Ancetti S, et al. 2023 clinical practice Guidelines on the Management of Atherosclerotic Carotid and Vertebral Artery Disease. Eur J Vasc Endovasc Surg. 2023;65:7‐111. 10.1016/j.ejvs.2022.04.011.
Simons LA, Simons J. Lipoprotein(a) and the risk of recurrent coronary heart disease: the Dubbo study. Curr Med Res Opin. 2023;39:933‐938. doi:10.1080/03007995.2023.2214434
Suzue A, Uno M, Kitazato KT, et al. Comparison between early and late carotid endarterectomy for symptomatic carotid stenosis in relation to oxidized low‐density lipoprotein and plaque vulnerability. J Vasc Surg. 2007;46:870‐875. doi:10.1016/j.jvs.2007.06.039
Polonskaya YV, Kashtanova EV, Murashov IS, et al. Association of matrix metalloproteinases with coronary artery calcification in patients with chd. J Pers Med. 2021;11:506. doi:10.3390/jpm11060506
Park JP, Lee BK, Shim JM, et al. Relationship between multiple plasma biomarkers and vulnerable plaque determined by virtual histology intravascular ultrasound. Circ J. 2010;74:332‐336. doi:10.1253/circj.CJ-09-0570
Loftus IM, Naylor AR, Goodall S, et al. Increased matrix metalloproteinase‐9 activity in unstable carotid plaques: a potential role in acute plaque disruption. Stroke. 2000;31:40‐47. doi:10.1161/01.STR.31.1.40
Olson FJ, Schmidt C, Gummesson A, et al. Circulating matrix metalloproteinase 9 levels in relation to sampling methods, femoral and carotid atherosclerosis. J Intern Med. 2008;263:626‐635. doi:10.1111/j.1365-2796.2008.01927.x
Brea D, Roquer J, Serena J, Segura T, Castillo J. Oxidative stress markers are associated to vascular recurrence in non‐cardioembolic stroke patients non‐treated with statins. BMC Neurol. 2012;12:65. doi:10.1186/1471-2377-12-65
Pejenaute Á, Cortés A, Marqués J, et al. NADPH oxidase overactivity underlies telomere shortening in human atherosclerosis. Int J Mol Sci. 2020;21:1‐11. doi:10.3390/ijms21041434